fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-03-25 Laboratorios Farmacéuticos Rovi (Spain)
Novartis Vaccines (Switzerland)
vaccines against seasonal and pandemic influenza / seasonal and pandemic influenza manufacturing
commercialization/ distribution
other
See details
2010-03-23 GTx (USA)
Ipsen (France)
toremifene (selective estrogen receptor modulator, or SERM) / estrogen related side effects of androgen deprivation for advanced prostate cancer
prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN)
licensing
commercialization/ distribution
See details
2010-03-23 Integrated Biobank of Luxembourg (IBBL - Luxembourg)
Life Technologies Corporation (USA)
/ personalized medicine and genetic causes of disease R&D
other
See details
2010-03-17 Evotec (Germany)
Hypha Discovery (UK)
natural product collection (MycoDiverse™ collection) R&D
other
See details
2010-03-16 ImmunID (France)
Roche (Switzerland)
solutions in the field of immunomonitoring R&D
See details
2010-03-12 Ipsen (France)
Rhythm Pharmaceuticals (USA)
peptide therapeutics (melanocortin and ghrelin programs) / obesity, metabolic diseases, and gastrointestinal disorders R&D
licensing
commercialization/ distribution
development
See details
2010-03-12 BioInvent International (Sweden)
Human Genome Sciences (USA)
therapeutic monoclonal antibodies R&D
manufacturing
commercialization/ distribution
development
See details
2010-03-11 Evotec (Germany)
Active Biotech (Sweden)
small molecule modulators of an undisclosed priority biological target / immune disorders, cancer R&D
other
See details
2010-03-11 Hemarina (France)
Abcys (France)
HEMOXCell® products for cell culture, HEMOXCell® Combo et HEMOXCell® Buffer
This additive for cell culture media uses marine worm haemoglobin as an oxygenation additive (See http://www.biopharmaceutiques.com/en/article/97_1774.html).
commercialization/ distribution
See details
2010-03-10 Cellzome (UK)
GSK (UK)
selective small-molecule drug candidates identified on the basis of the Episphere™ technology platform / immunoinflammatory diseases R&D
licensing
commercialization/ distribution
development
See details
2010-03-10 Transgene (France)
Novartis (Switzerland)
therapeutic vaccine TG4010 (MVA-MUC1-IL2) / non small cell lung cancer and other potential indications manufacturing
commercialization/ distribution
development
See details
2010-03-09 Lonza (Switzerland)
Odyssey Thera (USA)
Protein-fragment complementation assay technology licensing
See details
2010-03-08 Vernalis (UK)
Paul Capital Healthcare (USA)
Frovatriptan other
See details
2010-03-06 Ubiquigent (UK)
Stemgent (USA)
biological products and services generated by the SCottish Institute for ceLL Signalling manufacturing
other
See details
2010-03-03 NicOx (France)
Bausch & Lomb (USA)
NCX 116 (previously PF-03187207- nitric oxide-donating prostaglandin F2-alpha analog)

Last summer, Nicox has reacquired the full development and commercialization rights to PF-03187207 that have been licensed to Pfizer (See http://www.biopharmaceutiques.com/fr/tables/agreements_618.html) / glaucoma, ocular hypertension
licensing
commercialization/ distribution
development
See details
[<<]      «      4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13   |   14      »      [65]